Soleno Therapeutics (SLNO) Return on Equity: 2014-2017
Historic Return on Equity for Soleno Therapeutics (SLNO) over the last 3 years, with Dec 2017 value amounting to -0.14%.
- Soleno Therapeutics' Return on Equity rose 153.00% to -0.14% in Q4 2017 from the same period last year, while for Dec 2017 it was -0.14%, marking a year-over-year increase of 153.00%. This contributed to the annual value of -0.05% for FY2018, which is 19.00% up from last year.
- Soleno Therapeutics' Return on Equity amounted to -0.14% in Q4 2017, which was up 15.49% from -0.17% recorded in Q3 2017.
- In the past 5 years, Soleno Therapeutics' Return on Equity registered a high of 2.87% during Q3 2015, and its lowest value of -12.58% during Q4 2015.
- Its 3-year average for Return on Equity is -1.52%, with a median of -0.21% in 2017.
- Per our database at Business Quant, Soleno Therapeutics' Return on Equity tumbled by 1,293bps in 2015 and then skyrocketed by 1,091bps in 2016.
- Soleno Therapeutics' Return on Equity (Quarterly) stood at 0.35% in 2014, then slumped by 1,293bps to -12.58% in 2015, then surged by 1,091bps to -1.67% in 2016, then surged by 153bps to -0.14% in 2017.
- Its last three reported values are -0.14% in Q4 2017, -0.17% for Q3 2017, and -0.14% during Q2 2017.